Olympiad Research LP Makes New $147,000 Investment in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Olympiad Research LP purchased a new stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 31,530 shares of the company’s stock, valued at approximately $147,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. EP Wealth Advisors LLC purchased a new position in GoodRx in the 3rd quarter worth about $73,000. Sanctuary Advisors LLC bought a new stake in shares of GoodRx in the third quarter worth approximately $85,000. Sugar Maple Asset Management LLC purchased a new position in shares of GoodRx during the fourth quarter valued at approximately $122,000. Quest Partners LLC bought a new position in GoodRx during the third quarter valued at approximately $160,000. Finally, JPMorgan Chase & Co. boosted its holdings in GoodRx by 358.7% in the third quarter. JPMorgan Chase & Co. now owns 24,293 shares of the company’s stock worth $169,000 after purchasing an additional 18,997 shares during the last quarter. 63.77% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on GDRX. KeyCorp decreased their target price on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Barclays reduced their price objective on GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. Mizuho started coverage on GoodRx in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 target price on the stock. Morgan Stanley reduced their price target on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 17th. Finally, Citigroup lowered their price objective on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research note on Friday, January 10th. Five analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.38.

GoodRx Price Performance

Shares of NASDAQ:GDRX opened at $4.81 on Monday. The firm’s 50 day simple moving average is $4.67 and its two-hundred day simple moving average is $5.80. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The company has a market capitalization of $1.83 billion, a P/E ratio of -160.33, a P/E/G ratio of 2.46 and a beta of 1.28. GoodRx Holdings, Inc. has a 1-year low of $4.09 and a 1-year high of $9.26.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.